FCGR2A and cancer: This increase in affinity, beyond that previously reported for currently clinically used antibodies for cancer therapy, eliminates the need for the formation of a high-avidity immune complex otherwise needed for a WT IgG1 to robustly bind to FcγR and to be retained on immune effector cells sufficiently to engender prolonged immune surveillance.